© Copyright Acquisition International 2025 - All Rights Reserved.

Article Image - Avant Diagnostics and Amarantus Diagnostics to Combine with Theranostics Health
Posted 7th March 2016

Avant Diagnostics and Amarantus Diagnostics to Combine with Theranostics Health

Avant Diagnostics, Inc, a biotechnology company focused on the development of oncology based diagnostics, and Amarantus Diagnostics, Inc, a wholly-owned subsidiary of Amarantus BioScience Holdings, Inc, today announced that the companies have jointly entered into a letter of intent for Avant to acqu

Mouse Scroll AnimationScroll to keep reading

Let us help promote your business to a wider following.

Avant Diagnostics and Amarantus Diagnostics to Combine with Theranostics Health
Image

Avant Diagnostics, Inc., a biotechnology company focused on the development of oncology based diagnostics, and Amarantus Diagnostics, Inc, a wholly-owned subsidiary of Amarantus BioScience Holdings, Inc, today announced that the companies have jointly entered into a letter of intent for Avant to acquire assets and certain liabilities of Theranostics Health Incorporated, adding key CLIA laboratory and intellectual property capabilities to Avant’s previously announced letter of intent to merge with Amarantus Diagnostics (collectively, the “Transactions”).

THI currently generates over $1.5M in services revenue from some of the world’s leading biopharmaceutical companies, including 7 of the top 10 pharmaceutical companies by revenue. The companies will be holding a conference call to discuss the business combination today at 4:30 PM ET. To access the conference call please dial 215-383-1625 or toll free 800-356-8278; access code 135394.

Under the terms of the letter of intent, Avant shall issue to THI 25 million shares of its common stock upon the closing. Amarantus BioScience has provided a convertible note of $400,000 to THI to facilitate the transaction that will be assumed by Avant upon closing of the transactions. As previously disclosed, Avant plans to issue 80 million shares of its common stock to Amarantus Biosciences upon completion of its merger with Amarantus Diagnostics. The Transactions are expected to close in the first half of 2016, and are subject to customary closing conditions.

Gerald E. Commissiong, President & CEO of Amarantus said:

“THI is a leader in the area of signal transduction biology, where they have been able to attract an A-list of pharmaceutical customers collaborating with the company to evaluate the therapeutic benefit and potential of their drug candidates using THI’s proprietary assays.

“In addition, THI has a CLIA lab where Amarantus’ Diagnostics has established operations over the course of the first quarter that will allow for CLIA validation and commercial launch of the combined company’s suite of high-value, proprietary diagnostics in the areas of oncology and neurology. THI’s sales channel into the pharmaceutical industry will provide important leverage for the combined company to market the LymPro Test® for Alzheimer’s disease. We could not have picked a better partner to bring Avant and Amarantus’ Diagnostics leading-edge intellectual property in diagnostics and biomarkers to the market.”

Gregg Linn, President & CEO of Avant Diagnostics added:

“Key to the business case for the merged company is THI’s impressive pharma services revenue base and sales channel in the area of cell signaling biology. In addition to this, THI’s CLIA laboratory provides the combined company with the infrastructure to launch OvaDx®, MSPrecise® and LymPro Test in a regulatory compliant environment that has been vetted by some of the world’s top pharmaceutical companies. THI’s laboratory meets the highest quality standards under CLIA/CAP which should give both our pharmaceutical and commercial customers great confidence in the information generated in THI’s laboratory.”

THI’s core business is centred on providing pharmaceutical and biotechnical companies access to its technology for quantitatively measuring the activation status of key proteins and signal transduction pathways that are dysregulated in multiple disease processes via its Reverse-phase Protein Array (RPPA) platform. THI is experienced in running CAP-accredited assays in its CLIA laboratory for predicting response to therapies in difficult to treat cancers.  THI believes that, while genomic approaches may identify potential activating mutations in diseased tissues, measuring the actual activation status of the protein drug targets and the signal transduction pathways that they regulate, provides physicians with much-needed evidence that a particular therapeutic strategy can provide benefits to the patient.  THI has launched tests, TheraLink® Assays, for guiding therapeutic decisions in breast and colorectal cancer. The post-merger Avant Diagnostics will further build on its recognized scientific expertise in the area of cell cycle biology to increase its pharma services revenues and provide therapy guiding diagnostics in difficult to treat conditions.

Glenn Hoke, PhD, Chief Executive Officer of THI added:

“After an extensive evaluation of the diagnostics market, we believe that we have found the best potential partners in Avant and Amarantus. It is clear that we will be expanding our CLIA offerings with much needed tests such as OvaDx in cancer and MSPrecise in neurology, while also providing significant additional pharma services business development opportunities with the LymPro Test. With platforms in microarray proteomics, ELISA, flow cytometry and ‘next-gen’ sequencing, the combined company’s capabilities will allow it to add cross-platform diagnostics as we grow into the future.”

 

 

Categories: Innovation, M&A, Strategy


You Might Also Like
Read Full PostRead - Eye Icon
Acquisition (USD2.5b): Zillow/Trulia
Finance
27/02/2015Acquisition (USD2.5b): Zillow/Trulia

Acquisition International reports on Zillow, Inc.'s acquisition of Trulia, Inc. for $2.5 billion in a stock-for-stock transaction, and formed Zillow Group, Inc.

Read Full PostRead - Eye Icon
Travers Smith Advise Clayton, Dubilier & Rice’s Acquisition of Motor Fuel Group
M&A
17/06/2015Travers Smith Advise Clayton, Dubilier & Rice’s Acquisition of Motor Fuel Group

Travers Smith Advise Clayton, Dubilier & Rice's Acquisition of Motor Fuel Group

Read Full PostRead - Eye Icon
New Azure App Identifies Cloud Computing Costs
Innovation
05/05/2015New Azure App Identifies Cloud Computing Costs

A new Microsoft Azure app, which helps global organisations identify and track their cloud computing costs, is formally launched in the UK and globally today.

Read Full PostRead - Eye Icon
What is a Vendor Manager and Why Would You Want One For Your Business
News
04/07/2022What is a Vendor Manager and Why Would You Want One For Your Business

Vendors are often at the heart of an organization's operations and activities. They accelerate the growth of your company, help achieve profit goals and generate sizable revenue.

Read Full PostRead - Eye Icon
Indian Ingenuity in Educational Excellence
Innovation
04/02/2020Indian Ingenuity in Educational Excellence

For many students, learning and achieving academic success requires more than simply studying books. Feeling invested in and connected with can help students go above and beyond their limitations in striving for better careers. EduconIndia is helping students

Read Full PostRead - Eye Icon
Corporate Renewal – Why this is Vital to Businesses Globally
Innovation
31/08/2016Corporate Renewal – Why this is Vital to Businesses Globally

Based in Chicago, the Fennimore Group is a highly innovative company helping businesses accelerate activity adopting change, organising work processes, aligning organisational infrastructure, and ensuring the completion of all work stream functionality.

Read Full PostRead - Eye Icon
Enhancing Education
News
10/02/2023Enhancing Education

Award-winning Chatsworth Schools entered the private schools group market in 2018 with a passion for schools as learning communities and a commitment to excellence.

Read Full PostRead - Eye Icon
Is Buy-to-Let a Good Idea in 2023?
News
16/08/2023Is Buy-to-Let a Good Idea in 2023?

For generations, property investment has been a go-to choice for individuals seeking a passive income stream, regardless of economic fluctuations. The onset of the COVID pandemic shed new light on this age-old strategy, showcasing its potential as rental costs

Read Full PostRead - Eye Icon
Westinghouse Increases Commitment to Nuclear Industry with Acquisition
M&A
05/10/2016Westinghouse Increases Commitment to Nuclear Industry with Acquisition

Westinghouse Electric Company, LLC has signed a definitive agreement with AZZ Inc. to acquire Nuclear Logistics Inc. (NLI), the largest third-party supplier of safety-related equipment solutions to the nuclear industry. The acquisition supports Westinghouse’



Our Trusted Brands

Acquisition International is a flagship brand of AI Global Media. AI Global Media is a B2B enterprise and are committed to creating engaging content allowing businesses to market their services to a larger global audience. We have a number of unique brands, each of which serves a specific industry or region. Each brand covers the latest news in its sector and publishes a digital magazine and newsletter which is read by a global audience.

Arrow